TScan Therapeutics, Inc. (TCRX) Misses Q1 EPS by 4c

TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q1 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• AI/ML Innovations plans $2M private placement on the CSE
• Stripe, Advent In Talks To Buy Paypal - WSJ